Roughening of close-packed singular surfaces

An upper bound to the roughening temperature of a close-packed singular surface, fcc Al (111), is obtained via free energy calculations based on thermodynamic integration using the embedded-atom interaction model. Roughening of Al (111) is predicted to occur at around 890 K, well below bulk melting (933 K), and it should therefore be observable, save for possible kinetic hindering.Comment: RevTeX 4 pages, embedded figure

Nothing moves a surface: vacancy mediated surface diffusion

We report scanning tunneling microscopy observations, which imply that all atoms in a close-packed copper surface move frequently, even at room temperature. Using a low density of embedded indium `tracer' atoms, we visualize the diffusive motion of surface atoms. Surprisingly, the indium atoms seem to make concerted, long jumps. Responsible for this motion is an ultra-low density of surface vacancies, diffusing rapidly within the surface. This interpretation is supported by a detailed analysis of the displacement distribution of the indium atoms, which reveals a shape characteristic for the vacancy mediated diffusion mechanism that we propose.Comment: 4 pages; for associated movie, see http://www-lion.leidenuniv.nl/sections/cm/groups/interface/projects/therm

The impact of technology on the changing practice of lung SBRT

Stereotactic body radiotherapy (SBRT) for lung tumours has been gaining wide acceptance in lung cancer. Here, we review the technological evolution of SBRT delivery in lung cancer, from the first treatments using the stereotactic body frame in the 1990's to modern developments in image guidance and motion management. Finally, we discuss the impact of current technological approaches on the requirements for quality assurance as well as future technological developments

A novel flexible framework with automatic feature correspondence optimization for nonrigid registration in radiotherapy

Technical improvements in planning and dose delivery and in verification of patient positioning have substantially widened the therapeutic window for radiation treatment of cancer. However, changes in patient anatomy during the treatment limit the exploitation of these new techniques. To further improve radiation treatments, anatomical changes need to be modeled and accounted for. Non-rigid registration can be used for this purpose. This paper describes the design, the implementation and the validation of a new framework for non-rigid registration for radiotherapy applications. The core of this framework is an improved version of the Thin Plate Splines Robust Point Matching (TPS-RPM) algorithm. The TPS-RPM algorithm estimates a global correspondence and a transformation between the points that represent organs of interest belonging to two image sets. However, the algorithm does not allow for the inclusion of prior knowledge on the correspondence of subset of points and therefore, it can lead to inconsistent anatomical solutions. In this paper TPS-RPM was improved by employing a novel correspondence filter that supports simultaneous registration of multiple structures. The improved method allows for coherent organ registration and for the inclusion of user defined landmarks, lines and surfaces inside and outside of structures of interest. A procedure to generate control points form segmented organs is described. The framework parameters r and ?, which control the number of points and the non-rigidness of the transformation respectively, were optimized for three sites with different degrees of deformation: head and neck, prostate and cervix, using two cases per site. For the head and neck cases, the salivary glands were manually contoured on CT-scans, for the prostate cases the prostate and the vesicles, and for the cervix cases the cervix-uterus, the bladder and the rectum. The transformation error obtained using the best set of parameters was below 1 mm for all the studied cases. The length of the deformation vectors were on average (± 1 standard deviation) 5.8 ± 2.5 and 2.6 ± 1.1 mm for the head and neck cases, 7.2 ± 4.5 and 8.6 ± 1.9 mm for the prostate cases, and 19.0 ± 11.6 and 14.5 ± 9.3 mm for the cervix cases. Distinguishable anatomical features were identified for each case, and were used to validate the registration by calculating residual distances after transformation: 1.5 ± 0.8, 2.3 ± 1.0 and 6.3 ± 2.9 mm for the head and neck, prostate and cervix sites respectively. Finally, we demonstrated how the inclusion of these anatomical features in the registration process reduced the residual distances to 0.8 ± 0.5, 0.6 ± 0.5 and 1.3 ± 0.7 mm for the head and neck, prostate and cervix sites respectively. The inclusion of additional anatomical features produced more anatomically coherent transformations without compromising the transformation error. We concluded that the presented non-rigid registration framework is a powerful tool to simultaneously register multiple segmented organs with very different complexity

Are Vicinal Metal Surfaces Stable?

Quantum Matter and Optic

Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient-specific QA measurements

Purpose: To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three-dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA). Methods: The independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field-size dependent corrections). A set of 84 patient-specific quality assurance (QA) measurements for multi-leaf collimator (MLC) plans, using an Octavius two-dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels. Results: Of all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5-mm fixed cone. The profiles were compared using a one-dimensional gamma evaluation with 2% dose difference and 0.5 mm distance-to-agreement (Γ(2,0.5)). The off-centre ratios showed an average pass rate >99% (92–100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans. Conclusion: The first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patientspecific QA measurements in our clinic

Development of patient-specific pre-treatment verification procedure for FLASH proton therapy based on time resolved film dosimetry

Background: Pre-clinical studies demonstrate that delivering a high dose at a high dose rate result in less toxicity while maintaining tumor control, known as the FLASH effect. In proton therapy, clinical trials have started using 250 MeV transmission beams and more trials are foreseen. A novel aspect of FLASH treatments, compared to conventional radiotherapy, is the importance of dose rate next to dose and geometry. Therefore, to ensure the safety and quality of FLASH treatments, patient-specific dose-rate verification before treatment is an important additional prerequisite. Various definitions of dose rate have been reported, however, the scanning proton beam (PBS) dose rate definition of Folkerts 2020 is currently the most used. It is the ratio between delta dose (ΔD) and delta time (Δt), subject to a predefined threshold, for a given position. Gafchromic film is a widely available detector used to perform relative and absolute integrated dose measurements. Since the response time of film is in the order of micro seconds it could also be suitable for pre-treatment verification of FLASH proton therapy. Purpose: Development of a patient-specific pre-treatment verification procedure for FLASH proton therapy based on time resolved film dosimetry. The detector design is presented and validated using three tests. Methods: A dedicated setup was built that holds a Gafchromic film and a high-speed camera to record the film during the irradiations. The red color channel of the camera's readings was converted into optical density (OD) and an OD-to-dose calibration curve was applied to determine the relative dose accumulation over time. To undo the film measurement (film response) of the post-irradiation coloration process, it is assumed that each dose deposit (pulse) results in a similar film response function. The convolution of the film response function over the pulse provides the film response. First the film response function was obtained by fitting this parameter onto a known film response and corresponding pulse. Post-irradiation coloration correction was performed by deconvoluting all film measurement by the obtained film response function. From the integral of each measured pulse, the Δt was obtained. Several validation tests were conducted: compare the Δt film measurement to a reference detector, exclude that revisiting spots result in an unwanted artefact on the dose accumulation measurement and thereby Δt, and compare Δt distributions of film measurement and simulation (local gamma evaluation, criteria 10%/2 mm) for nine QA fields (dose values; 12, 15, and 20 Gy, and, nozzle currents; 25, 120, and 215 nA). A similar analysis was performed for three dose optimized treatment beams, with and without scan patterns optimized on local dose rate. Results: Good agreement was found for Δt comparing film to the reference detector, but for Δt values smaller than ∼20 ms the error becomes larger (≥15%). Dose accumulation measured with film over time from a single spot is independent of whether the dose is delivered at once, twice or thrice. All gamma evaluations resulted in a gamma pass rate of ≥90%. Conclusions: Time resolved film dosimetry to perform patient-specific pre-treatment verification in FLASH proton therapy is feasible.</p

Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy:A longitudinal study

Objective: In comparison to current standard photon irradiation, proton therapy (PT) significantly reduces dose to the surrounding normal tissue and therefore is expected to reduce toxicity and improve health related quality of life (HRQoL). Despite the high expectations of PT, there is very limited data on patients’ HRQoL after radiotherapy. This study evaluated HRQoL in head and neck cancer (HNC) patients receiving PT and established a robust benchmark for future comparison of PT and the radiotherapy advancements. Method: A questionnaire-based (consisting of EORTC-QLQ-C30, EQ-5D, and EORTC-H&amp;N-35) prospective cohort study was performed in a Dutch proton therapy center. HNC patients who received PT between January 2020 to December 2022 were enrolled in this study. The questionnaires were distributed pre-treatment, and 0, 6, 12, 24 months post-treatment. The generalized estimating equations method was used to analyze the utility change and negative impact of the radiation-related toxicities. Results: 119 HNC patients were included in the study. Symptom and function scores showed the deterioration of all reported functions during the period of treatment. Most of the functions recovered within six months and improved beyond baseline. At the end of PT, the patients’ utility decreased significantly (0.12 points) compared to the baseline. The loss in utility was recovered after six months and a further improvement was seen one year after the treatment. This study further provided the estimation of the disutility of each radiation related toxicity. Conclusion: The present study presented the impact of toxicity on patient's utility over time and further confirmed it with the results of patient-reported symptom and function. This study provided estimation of each radiation-related toxicity, including xerostomia, dysphagia, mucositis, and dermatitis, which could contribute to the value assessment through economic evaluations of PT.</p